118 related articles for article (PubMed ID: 1463767)
21. Purine metabolizing enzymes as predictors of lymphoblast sensitivity to deoxyadenosine.
Mitchell BS; Edwards NL
J Lab Clin Med; 1984 Sep; 104(3):414-24. PubMed ID: 6147383
[TBL] [Abstract][Full Text] [Related]
22. Differential production of deoxyadenosine by human T and B lymphoblasts.
Iizasa T; Kubota M; Carson DA
J Immunol; 1983 Oct; 131(4):1776-9. PubMed ID: 6352803
[TBL] [Abstract][Full Text] [Related]
23. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
24. Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase.
Carson DA; Wasson DB; Lakow E; Kamatani N
Proc Natl Acad Sci U S A; 1982 Jun; 79(12):3848-52. PubMed ID: 6808516
[TBL] [Abstract][Full Text] [Related]
25. Dipyridamole enhancement of toxicity to L1210 cells by deoxyadenosine and deoxycoformycin combinations in vitro.
Kang GJ; Kimball AP
Cancer Res; 1984 Feb; 44(2):461-6. PubMed ID: 6362851
[TBL] [Abstract][Full Text] [Related]
26. Plasma deoxyadenosine, adenosine, and erythrocyte deoxyATP are elevated at birth in an adenosine deaminase-deficient child.
Hirschhorn R; Roegner V; Rubinstein A; Papageorgiou P
J Clin Invest; 1980 Mar; 65(3):768-71. PubMed ID: 6965496
[TBL] [Abstract][Full Text] [Related]
27. Morphological changes in leukemic lymphoblasts and normal lymphocytes treated with deoxyadenosine plus deoxycoformycin.
Matsumoto SS; Yu AL; Yu J
Cancer Invest; 1985; 3(3):225-33. PubMed ID: 3873981
[TBL] [Abstract][Full Text] [Related]
28. Deoxyadenosine-resistant human T lymphoblasts with elevated 5'-nucleotidase activity.
Carson DA; Carrera CJ; Wasson DB; Iizasa T
Biochim Biophys Acta; 1991 Jan; 1091(1):22-8. PubMed ID: 1995064
[TBL] [Abstract][Full Text] [Related]
29. Influence of adenosine deaminase inhibition on the phosphoinositide turnover in the initial stages of human T cell activation.
Buc HA; Moncion A; Hamet M; Houllier AM; Thuilier L; Perignon JL
Eur J Immunol; 1990 Mar; 20(3):611-5. PubMed ID: 2156710
[TBL] [Abstract][Full Text] [Related]
30. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.
Carson DA; Wasson DB; Kaye J; Ullman B; Martin DW; Robins RK; Montgomery JA
Proc Natl Acad Sci U S A; 1980 Nov; 77(11):6865-9. PubMed ID: 6256765
[TBL] [Abstract][Full Text] [Related]
31. DNA strand breaks induced in human T-lymphocytes by the combination of deoxyadenosine and deoxycoformycin.
Brox L; Ng A; Pollock E; Belch A
Cancer Res; 1984 Mar; 44(3):934-7. PubMed ID: 6607110
[TBL] [Abstract][Full Text] [Related]
32. Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells.
Mitchell BS; Mejias E; Daddona PE; Kelley WN
Proc Natl Acad Sci U S A; 1978 Oct; 75(10):5011-4. PubMed ID: 311004
[TBL] [Abstract][Full Text] [Related]
33. The combination of adenosine deaminase inhibition and deoxyadenosine induces apoptosis in a human astrocytoma cell line.
Garcia-Gil M; Tozzi MG; Varani S; Della Verde L; Petrotto E; Balestri F; Colombaioni L; Camici M
Neurochem Int; 2015 Jan; 80():14-22. PubMed ID: 25447764
[TBL] [Abstract][Full Text] [Related]
34. Deoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblasts.
Mann GJ; Fox RM
J Clin Invest; 1986 Nov; 78(5):1261-9. PubMed ID: 3490493
[TBL] [Abstract][Full Text] [Related]
35. Activation of deoxycytidine kinase by deoxyadenosine: implications in deoxyadenosine-mediated cytotoxicity.
Keszler G; Virga S; Spasokoukotskaja T; Bauer PI; Sasvari-Szekely M; Staub M
Arch Biochem Biophys; 2005 Apr; 436(1):69-77. PubMed ID: 15752710
[TBL] [Abstract][Full Text] [Related]
36. [Polyethylene glycol-adenosine deaminase: a new adenosine deaminase deficiency therapy. Value of deoxyadenosine triphosphate determination for therapeutic monitoring].
Bory C; Boulieu R; Souillet G; Hershfield MS
Therapie; 1991; 46(4):323-6. PubMed ID: 1948809
[TBL] [Abstract][Full Text] [Related]
37. Characterization of adenosine deaminase (ADA)-negative B-lymphoblastoid cells cocultured with ADA-positive fibroblasts.
Fujita M; Ito K; Kawamoto H; Kashii S; Norioka M; Monden S; Okuma M
Eur J Haematol; 1993 Apr; 50(4):200-5. PubMed ID: 8500601
[TBL] [Abstract][Full Text] [Related]
38. Deoxyadenosine triphosphate acting as an energy-transferring molecule in adenosine deaminase inhibited human erythrocytes.
Nakashima K; Nakashima H; Shimoyama M
Biochim Biophys Acta; 1991 Sep; 1094(3):257-62. PubMed ID: 1911876
[TBL] [Abstract][Full Text] [Related]
39. Interference of deoxyadenosine with transmembrane signaling events in human T lymphocytes.
Scharenberg JG; Rijkers GT; Akkerman JW; Staal GE; Zegers BJ
Int J Immunopharmacol; 1990; 12(1):113-20. PubMed ID: 2303314
[TBL] [Abstract][Full Text] [Related]
40. Decreased methionine synthesis in purine nucleoside-treated T and B lymphoblasts and reversal by homocysteine.
Boss GR; Pilz RB
J Clin Invest; 1984 Oct; 74(4):1262-8. PubMed ID: 6332827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
